Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
- Conditions
- Non-Small Cell Lung CarcinomaVenous Thromboembolism
- Registration Number
- NCT00192829
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Histologically or cytologically confirmed diagnosis of NSCLC.
- normal serum bilirubin
- informed concent to participate in the study
Exclusion Criteria
- anticoagulant therapy
- infectious disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What hypercoagulable biomarkers predict thrombotic events in advanced NSCLC patients?
How do hypercoagulable parameters correlate with prognosis in NSCLC compared to other cancers?
What molecular mechanisms link coagulation pathways to NSCLC progression and metastasis?
Are there specific adverse events associated with hypercoagulable states in NSCLC patients?
What combination therapies improve thrombosis outcomes in NSCLC beyond standard anticoagulants?
Trial Locations
- Locations (2)
Hematology Laboratory
🇮🇱Haifa, Israel
Oncology Institution, Rambam Health Campus
🇮🇱Haifa, Israel
Hematology Laboratory🇮🇱Haifa, IsraelGalit Sarig, Ph.DPrincipal Investigator